Media
"The mechanism of action is unique and brilliant"
For over 40 years, Dr. Harin Padma-Nathan has been at the forefront of developing treatments for erectile dysfunction. In an interview in Dicot Pharma's 2025 annual report, he describes why LIB-01 captured his interest...
How Dicot Pharma Is Rethinking Erectile Dysfunction from the Ground Up
A plant-derived compound with a novel mechanism, eight weeks of effect from three days of dosing, and a Phase 2A readout that challenges what treatment of erectile dysfunction actually means...
VD och CFO presenterar bokslutskommuniké 2025 i Direkt Studios februari 2026
Scrip Asks... What Does 2026 Hold For Biopharma?
At the turn of each year, the global pharmaceutical news publication Scrip invites executives, investors and industry experts from across the global biopharma ecosystem to share their strategic outlook for the year ahead. This year, Elin Trampe, CEO of Dicot Pharma, is among them.
Därför påverkar erektionsproblem livslång hälsa
Behandling av erektil dysfunktion lyfts alltmer fram som en viktig del inom det växande fältet longevity där fokus ligger på hälsosamt åldrande – livskvalitet i strävan efter ett långt liv. I en amerikansk rapport pekas svenska Dicot Pharma och bolagets forskning inom potensläkemedel ut som ett framtidsföretag.